Agilent moves Cell Analysis Division into Diagnostics and Genomics Group

AGILENT TECHNOLOGIES, INC.

Cell Analysis Division moved from LSAG to DGG; effective Q1 fiscal 2024.
Reorganization aims to strengthen growth opportunities and align with customer workflows.
Historical segment financials for three prior years will be recast and filed in January 2024.
Cell Analysis built via acquisitions of BioTek, ACEA, and Seahorse; remains key growth driver.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.